Publication | Open Access

LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

Second Progression-free SurvivalMedicineLba33 MaintenanceCancer ManagementGynecologyCancer TreatmentOncologyRadiation OncologyGynecology OncologyMolecular OncologyOvarian CancerFinal Analysis